Enhancement of the *in vivo* persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA

Yun Bai¹, Shifeng Kan¹, Shixin Zhou¹, Yuting Wang¹, Jun Xu², John P Cooke⁴, Jinhua Wen¹, Hongkui Deng^{1,2,3}

¹Department of Cell Biology and Stem Cell Research Center, School of Basic Medical Sciences, Center for Molecular and Translational Medicine, Peking University Health Science Center, Beijing, China; ²The MOE Key Laboratory of Cell Proliferation and Differentiation, College of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China; ³Shenzhen Stem Cell Engineering Laboratory, Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen, China; ⁴Department of Cardiovascular Sciences, Center for Cardiovascular Regeneration, The Methodist Hospital Research Institute, Houston, TX, USA

Cell Discovery (2016) 2, 16032; doi:10.1038/celldisc.2016.32; published online 30 August 2016

Correction to: Cell Discovery (2015) 1, 15040; doi:10.1038/celldisc.2015.40; published online 8 December 2015

In the initial published version of this article, there was an inadvertent omission from the Acknowledgements that the contribution of John P Cooke to this work was funded in part by a Core Facility Support Award from the Cancer Prevention and Research Institute of Texas (RP150611). This omission does not affect the description of the results or the conclusions of this paper.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/